Advertisement

Advertisement

APVO Stock Latest News

Aptevo to Present CD40 Multispecific Cancer Platform

Company AnnouncementsAptevo to Present CD40 Multispecific Cancer Platform

Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs

PremiumCompany Announcements

Aptevo Advances Next-Generation Trispecific Immuno-Oncology Programs

28d ago

Aptevo Therapeutics advances trispecific candidate toward clinical development

PremiumThe Fly

Aptevo Therapeutics advances trispecific candidate toward clinical development

28d ago

Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes

PremiumCompany Announcements

Aptevo Shareholders Approve Equity Issuance, Reject Charter Changes

28d ago

Aptevo AML data ‘highly encouraging,’ says Roth Capital

PremiumThe Fly

Aptevo AML data ‘highly encouraging,’ says Roth Capital

2M ago

Aptevo Reports Promising Mipletamig Data in TP53-Mutant AML

PremiumCompany AnnouncementsAptevo Reports Promising Mipletamig Data in TP53-Mutant AML

2M ago

Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia

The Fly

Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia

2M ago

Aptevo Shareholders Back Board, Auditor and Incentive Plan

Company Announcements

Aptevo Shareholders Back Board, Auditor and Incentive Plan

2M ago

Aptevo Therapeutics files to sell 6.44M shares of common stock for holders

PremiumThe Fly

Aptevo Therapeutics files to sell 6.44M shares of common stock for holders

2M ago

Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds

PremiumThe Fly

Aptevo Therapeutics announces exercise of warrants, PIPE for $4.5M in proceeds

2M ago

Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30

PremiumThe Fly

Aptevo Therapeutics reports $9.8M in cash, cash equivalents as of June 30

2M ago

Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing

PremiumCompany Announcements

Aptevo Therapeutics Raises Capital Through Warrant-Induced Financing

2M ago

Aptevo Therapeutics Unveils New Solid Tumor Strategy

PremiumCompany AnnouncementsAptevo Therapeutics Unveils New Solid Tumor Strategy

3M ago

Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone

The Fly

Aptevo files patent application for Nectin-4 x PD-L1 dual-targeting backbone

3M ago

Aptevo Therapeutics Secures Grant for APVO451 Development

Company Announcements

Aptevo Therapeutics Secures Grant for APVO451 Development

4M ago

Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund

PremiumThe Fly

Aptevo Therapeutics awarded $1.5M research grant from Andy Hill CARE Fund

4M ago

Aptevo Therapeutics appoints Janatpour as SVP, CSO

PremiumThe Fly

Aptevo Therapeutics appoints Janatpour as SVP, CSO

5M ago

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave

PremiumCompany Announcements

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave

5M ago

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

PremiumThe Fly

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

5M ago

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

PremiumThe FlyAptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

5M ago

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

The Fly

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

6M ago

Aptevo Highlights Strong Phase 1b AML Trial Results

Company Announcements

Aptevo Highlights Strong Phase 1b AML Trial Results

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >